Bibliografia
Mirza F, Canalis E (2015) Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 173:131–151
Colangelo L, Biamonte F, Pepe J et al. (2019) Understanding and managing secondary osteoporosis. Expert Rev Endocrinol Metab 14:111–122
Nuti R, Brandi ML, Checchia G et al. (2019) Guidelines for the management of osteoporosis and fragility fractures. Intern Emerg Med 14:85–102
Nguyen KD, Bagheri B, Bagheri H (2018) Drug-induced bone loss: a major safety concern in Europe. Expert Opin Drug Saf 17:1005–1014
Compston J (2018) Glucocorticoid-induced osteoporosis: an update. Endocrine 61:7–16
Krajcovicova A, Hlavaty T, Killinger Z et al. (2014) Combination therapy with an immunomodulator and anti-TNF\(\alpha \) agent improves bone mineral density in IBD patients. J Crohns Colitis 8:1693–1701
Oh HJ, Ryu KH, Park BJ et al. (2018) Osteoporosis and osteoporotic fractures in gastrointestinal disease. J Bone Metab 25:213–217
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflitto di interesse
Gli autori Chiara Sonato, Jessica Pepe, Luciano Colangelo, Piergianni Biondi, Marco Occhiuto, Cristiana Cipriani e Salvatore Minisola dichiarano di non avere conflitti di interesse.
Consenso informato
Lo studio presentato in questo articolo non ha richiesto sperimentazione umana.
Studi sugli animali
Gli autori di questo articolo non hanno eseguito studi sugli animali.
Additional information
Nota della casa editrice
Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.
Rights and permissions
About this article
Cite this article
Sonato, C., Pepe, J., Colangelo, L. et al. Osteoporosi secondarie. L'Endocrinologo 21 (Suppl 1), 39–41 (2020). https://doi.org/10.1007/s40619-020-00707-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-020-00707-1